Evidence map›Paper›PMID 35384401›Full record

ArticleCurrent protocols2022

In Vivo Assessment of Ferroptosis and Ferroptotic Stress in Mice.

Kana Ide, Tomokazu Souma

Open access · greenAbstract read
In one paragraph

Article in Current protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kana IdeDivision of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Tomokazu SoumaDivision of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.ORCID https://orcid.org/0000-0002-3285-8613
Duke University · US

Funding

Therapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAPER, H WILLIAM · 2018 to 2022
$5.7M
Targeting Renal Tubular Epithelial Progenitors in AKI to CKD transitionR01DK123097 · NIDDK · DUKE UNIVERSITY · PI SOUMA, TOMOKAZU · 2020 to 2024
$2.2M
Live cell widefield fluorescence microscope with activation and bleaching lasersS10RR027528 · NCRR · DUKE UNIVERSITY · PI JOHNSON, SAM · 2010 to 2010
$423k
NCRR NIH HHS S10 RR027528NIDDK NIH HHS P30 DK114857NIDDK NIH HHS R01 DK123097
6 · The paper itself

Abstract

Ferroptosis is iron-dependent, lipid peroxidation-driven, regulated cell death that is triggered when cellular glutathione peroxidase 4 (GPX4)-mediated cellular defense is insufficient to prevent pathologic accumulation of toxic lipid peroxides. Ferroptosis is implicated in various human pathologies, including neurodegeneration, chemotherapy-resistant cancers, ischemia-reperfusion injury, and acute and chronic kidney diseases. Despite the fact that the ferroptotic process has been rigorously interrogated in multiple preclinical models, the lack of specific and readily available biomarkers to detect ferroptosis in vivo in mouse models makes it challenging to delineate its contribution to key pathologic events in vivo. Critical steps to practically evaluate ferroptosis include, but are not limited to, detecting increased cell death and pathologic accumulation of toxic lipid peroxides and testing augmentation of observed pathologic events by genetic inhibition of the glutathione-GPX4 axis or mitigation of the pathologic process by ferroptosis inhibitors. Here, we describe methods to evaluate these key features of the ferroptotic process in mice in vivo. Specifically, we describe methods to detect toxic lipid peroxides (4-hydroxynonenal) and cell death (based on terminal deoxynucleotidyl transferase dUTP nick end labeling staining) as well as a protocol to pharmacologically inhibit ferroptotic stress using liproxstatin-1. These protocols provide tools for understanding the ferroptotic process in mouse genetic or disease models. © 2022 Wiley Periodicals LLC. Basic Protocol 1: How to use liproxstatin-1 Basic Protocol 2: How to evaluate ferroptosis in mouse kidneys.

Indexed as

FerroptosisAnimalsCell DeathIronLipid PeroxidationLipid PeroxidesMiceIronLipid Peroxides4-HNE4-hydroxynonenalferroptosisliproxstatin-1mouse disease models

Identifiers

PMID35384401
PMCPMC9078574
OpenAlexW4224007456

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.